Minerva Surgical, Inc. (UTRS)
Minerva Surgical, Inc. operates in the Medical - Healthcare Information Services industry of the Healthcare sector, headquartered in Santa Clara, CA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $888. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -67.8%. Its beta of 4.60 implies it has historically moved more than the broad market.
Minerva Surgical, Inc. functions as a commercial-stage medical technology enterprise, specializing in the creation, production, and distribution of innovative, minimally invasive solutions tailored to address the uterine healthcare needs of women throughout the United States. Their suite of offerings features advanced endometrial ablation systems, including the Minerva ES and Genesys HTA. They also provide the Symphion Tissue Removal System, a sophisticated, minimally invasive device for uterine tissue removal that uniquely integrates bladeless tissue resection, coagulation capabilities, continuous visualization during procedures, and precise intrauterine pressure monitoring. Additionally, the Resectr Tissue Resection Device is a handheld surgical tool engineered for the hysteroscopic removal and diagnostic evaluation of endometrial polyps. These specialized instruments are utilized by obstetrician-gynecologists across a variety of clinical settings, such as hospitals, outpatient ambulatory surgical centers, and private physician practices. The company was founded in 2008 and is headquartered in Santa Clara, California.
Minerva Surgical, Inc. is most often compared with the following Healthcare names: